BR0110892A - Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos - Google Patents

Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos

Info

Publication number
BR0110892A
BR0110892A BR0110892-1A BR0110892A BR0110892A BR 0110892 A BR0110892 A BR 0110892A BR 0110892 A BR0110892 A BR 0110892A BR 0110892 A BR0110892 A BR 0110892A
Authority
BR
Brazil
Prior art keywords
peptides
pharmaceutical administration
processes
preparation
administration form
Prior art date
Application number
BR0110892-1A
Other languages
English (en)
Inventor
Horst Bauer
Michael Damm
Werner Sarlikiotis
Original Assignee
Zentaria Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaria Ag filed Critical Zentaria Ag
Publication of BR0110892A publication Critical patent/BR0110892A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMA DE ADMINISTRAçãO FARMACêUTICA PARA PEPTìDIOS, PROCESSOS PARA PREPARAçãO E USO DOS MESMOS". A invenção refere-se a formas de administração farmacêuticas, apropriadas para aplicação parenteral, que contêm peptídios dissolvidos ou dispersos, que tendem à agregação, na forma de seus sais de acetato, gluconato, glucuronato, lactato, citrato, benzoato ou fosfato e que também compreendem um dos ácidos acima citados como ácido livre.
BR0110892-1A 2000-05-18 2001-05-16 Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos BR0110892A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10024451A DE10024451A1 (de) 2000-05-18 2000-05-18 Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
PCT/EP2001/005555 WO2001087265A2 (de) 2000-05-18 2001-05-16 Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung

Publications (1)

Publication Number Publication Date
BR0110892A true BR0110892A (pt) 2003-03-11

Family

ID=7642584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110892-1A BR0110892A (pt) 2000-05-18 2001-05-16 Forma de administração farmacêutica para peptìdios, processos para preparação e uso dos mesmos

Country Status (24)

Country Link
US (2) US7718599B2 (pt)
EP (1) EP1282400B1 (pt)
JP (2) JP4944340B2 (pt)
KR (1) KR100580142B1 (pt)
CN (1) CN100342908C (pt)
AR (1) AR028588A1 (pt)
AU (1) AU777185B2 (pt)
BG (1) BG65976B1 (pt)
BR (1) BR0110892A (pt)
CA (1) CA2348167C (pt)
CZ (1) CZ303981B6 (pt)
DE (1) DE10024451A1 (pt)
HU (1) HUP0302050A3 (pt)
IL (1) IL152479A (pt)
MX (1) MXPA02011389A (pt)
NO (1) NO20025277L (pt)
NZ (1) NZ522381A (pt)
PL (1) PL203958B1 (pt)
RU (1) RU2253438C2 (pt)
SK (1) SK288118B6 (pt)
TW (1) TWI243059B (pt)
UA (1) UA74578C2 (pt)
WO (1) WO2001087265A2 (pt)
ZA (1) ZA200208761B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
JP4940492B2 (ja) * 2000-09-04 2012-05-30 大正製薬株式会社 鉄化合物配合内服液剤
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
RS52966B (sr) * 2002-09-27 2014-02-28 Zentaris Gmbh Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
EP1987843A3 (en) * 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
RU2358721C1 (ru) * 2005-04-15 2009-06-20 Виктор Павлович Кутняк Антинеопластический препарат (варианты)
RU2013128357A (ru) * 2010-12-06 2015-01-20 Астрон Рисёрч Лимитед Стабильный готовый к применению инъекционный раствор цетрореликса
CN102144980B (zh) * 2011-03-07 2013-01-09 深圳市健元医药科技有限公司 一种更加稳定的lhrh拮抗剂冻干粉针剂
EA201692083A1 (ru) * 2014-04-16 2017-03-31 Вейкс-Фарма Гмбх Фармацевтическая композиция для ветеринарии и ее применение
CN110234336A (zh) * 2017-01-31 2019-09-13 维鲁公司 用于促性腺激素释放激素(GnRH)拮抗剂的长效释放的组合物和方法
JP2022537957A (ja) * 2019-06-17 2022-08-31 インタス ファーマシューティカルズ リミテッド セトロレリクスの安定な製剤
RS62754B1 (sr) * 2019-10-24 2022-01-31 Sun Pharmaceutical Ind Ltd Stabilan parenteralni dozni oblik cetroreliks acetata
EP4164608A1 (en) * 2021-06-25 2023-04-19 Extrovis AG Pharmaceutical compositions
AU2022325518A1 (en) * 2021-08-11 2024-03-14 Rk Pharma Inc. Ready to use compositions of cetrorelix acetate
CN115969954A (zh) * 2023-01-09 2023-04-18 开封明仁药业有限公司 一种注射用西曲瑞克冻干药物组合物及其制备方法
EP4534074A1 (en) * 2023-10-04 2025-04-09 Ares Trading S.A. Liquid cetrorelix composition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE141996C (pt)
DD141996A1 (de) * 1979-02-21 1980-06-04 Ingrid Wolf Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
JPS5892620A (ja) * 1981-11-28 1983-06-02 Sunstar Inc インタ−フエロン安定配合組成物
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
DK163689A (da) * 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
JPH0725662B2 (ja) * 1990-10-22 1995-03-22 アース製薬株式会社 使用時調製型上皮細胞成長因子含有水性薬剤の安定化方法
US5643878A (en) * 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
JP3608802B2 (ja) * 1991-09-20 2005-01-12 第一サントリーファーマ株式会社 安定なカルシトニン医薬組成物及びその製造法
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
WO1994008605A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Therapeutic microemulsions
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
JP3636480B2 (ja) * 1993-05-19 2005-04-06 科研製薬株式会社 凍結乾燥製剤
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP2915296B2 (ja) * 1993-08-30 1999-07-05 宇野 潤 抗真菌製剤
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
DE69519382T3 (de) * 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
DE726075T1 (de) * 1995-02-08 1996-12-12 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
DE19542837A1 (de) * 1995-11-17 1997-05-22 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung
PT814778E (pt) * 1995-03-10 2001-11-30 Roche Diagnostics Gmbh Formas de administracao farmaceuticas contendo polipeptidos sob a forma de microparticulas e processo para a sua preparacao
US5942493A (en) * 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
IT1282733B1 (it) * 1996-05-20 1998-03-31 Flarer S A Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
AU7904998A (en) * 1997-07-07 1999-02-08 Peptichemio Ag Pharmaceutical composition containing peptichemio
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
AU5649299A (en) * 1998-09-11 2000-04-03 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method for stabilizing the same
EP0998940A1 (en) * 1998-09-30 2000-05-10 Laboratoire Theramex Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6911455B2 (en) * 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations

Also Published As

Publication number Publication date
TWI243059B (en) 2005-11-11
AR028588A1 (es) 2003-05-14
AU7404101A (en) 2001-11-26
AU777185C (en) 2001-11-26
CN100342908C (zh) 2007-10-17
AU777185B2 (en) 2004-10-07
US7718599B2 (en) 2010-05-18
HK1058622A1 (zh) 2004-05-28
IL152479A (en) 2013-08-29
ZA200208761B (en) 2002-11-29
SK17162002A3 (sk) 2003-07-01
IL152479A0 (en) 2003-05-29
HUP0302050A3 (en) 2012-11-28
EP1282400B1 (de) 2016-12-14
BG65976B1 (bg) 2010-08-31
US20050159335A1 (en) 2005-07-21
JP4944340B2 (ja) 2012-05-30
PL363007A1 (en) 2004-11-15
WO2001087265A2 (de) 2001-11-22
CA2348167C (en) 2012-01-10
CA2348167A1 (en) 2001-11-18
JP2003533466A (ja) 2003-11-11
US7696149B2 (en) 2010-04-13
MXPA02011389A (es) 2003-04-25
UA74578C2 (uk) 2006-01-16
WO2001087265A3 (de) 2002-04-18
RU2253438C2 (ru) 2005-06-10
EP1282400A2 (de) 2003-02-12
KR100580142B1 (ko) 2006-05-16
CN1469734A (zh) 2004-01-21
BG107312A (bg) 2003-06-30
KR20030036179A (ko) 2003-05-09
NO20025277D0 (no) 2002-11-04
NZ522381A (en) 2004-07-30
DE10024451A1 (de) 2001-11-29
PL203958B1 (pl) 2009-11-30
US20020039996A1 (en) 2002-04-04
JP2011213733A (ja) 2011-10-27
CZ20023969A3 (cs) 2003-05-14
NO20025277L (no) 2002-11-04
CZ303981B6 (cs) 2013-07-31
HUP0302050A2 (hu) 2003-09-29
SK288118B6 (sk) 2013-09-03

Similar Documents

Publication Publication Date Title
CY1110264T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ευαισθητα σε ρη συμπολυμερη τυπου μπλοκ και υδροφοβο φαρμακο
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR0011772A (pt) Conjugado de droga-oligÈmero, composição farmacêutica, método de solubilização de uma droga em uma microemulsão, e, métodos para fornecer um conjugado de droga ativa - hidrófilo e um conjugado de droga ativa - peg a um sìtio de um indivìduo
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
ES2091441T3 (es) Composicion farmaceutica.
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BR0211289A (pt) Derivados de dolastatina 10
KR920700679A (ko) 비(nasal) 전달용 지질부형제와 그 사용법
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
BR0108678A (pt) Novos compostos
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
ATE305775T1 (de) Tulobuterol enthaltendes präparat für perkutane absorption
CA2567857A1 (en) Irinotecan liposome formulation
MXPA02011389A (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y aplicacion.
DE60317039D1 (de) Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
DE60116483D1 (de) Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
BR0308316A (pt) Sais de nateglinida
BR9912375A (pt) Sais de nitrato, composições farmacêuticas, uso de sais e composições, e, processo para preparação de sais de nitrato.
BR9801150A (pt) Derivados de propanolamina, processos para a preparação deles, produtos farmacêuticos compreendendo esses compostos e uso dos mesmos.
EP1226829A3 (de) Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
BR9905832A (pt) Formulações de clorohexidina, sais de clorohexidina, soluções contendo estes sais e seu uso
BR0016130A (pt) Composto, formulação farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BLITZ F02-570 GMBH (DE)

Free format text: TRANSFERIDO POR FUSAO DE: ZENTARIS AG

B25D Requested change of name of applicant approved

Owner name: ZENTARIS GMBH (DE)

Free format text: ALTERADO DE: BLITZ F02-570 GMBH

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19/08/2008 POR TER SIDO APRESENTADO PROTOCOLO DE ESCLARECIMENTO NO420805362185 DE 01/09/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/08, 9/19, 47/12, 47/26, 47/40; A61P 13/08, 15/00, 17/00, 35/00, 5/24, 13/00, 5/00

Ipc: A61K 9/08 (2011.01), A61K 9/19 (2011.01), A61K 47/

B25G Requested change of headquarter approved

Owner name: ZENTARIS GMBH (DE)

Free format text: SEDE ALTERADA CONFORME PET NO 020060058923 - RJ DE 27/04/2006.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE RPI 2476 DE 19/06/2018